Oncotex Inc News Today

Affordable rapid multiplexed biomarker detection at the point-of-care for patients and practitioners...

IQX Limited (NSX:IQX) today announced it has received a worldwide license from Harvards Office of Technology Development to commercialise diagnostic technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University.

IQX Limited (NSX:IQX) is pleased to announce that OncoTEX Inc has received licensing for a gold compound platform technology that induces the bodys immune system to destroy cancer cells.

A member of The iQ Group Global, iQX Limited is an investment funds management company specialising in the bioscience sector that is committed to eradicating disease through capital investment.

/PRNewswire/ -- OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased to announce it has acquired a gold...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

IQX Limited (NSX:IQX) Progress of Clinical Programs    Progress of Clinical ProgramsSydney, April 29, 2021 AEST (ABN Newswire) - iQX Limited (iQX Ltd) ( NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository. The study follows a partners...